Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01072773|
Recruitment Status : Completed
First Posted : February 22, 2010
Results First Posted : December 5, 2012
Last Update Posted : April 2, 2014
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with combination chemotherapy may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving bortezomib, cyclophosphamide, and dexamethasone together works in treating patients with primary systemic light chain amyloidosis.
|Condition or disease||Intervention/treatment||Phase|
|Primary Systemic Amyloidosis||Drug: bortezomib Drug: cyclophosphamide Drug: dexamethasone||Phase 2|
I. To assess the confirmed hematologic response rate of the combination of bortezomib, cyclophosphamide and dexamethasone in patients with primary systemic amyloidosis.
I. Organ response rate of the bortezomib, cyclophosphamide and dexamethasone combination.
II. Severity and frequency of adverse events associated with bortezomib, cyclophosphamide and dexamethasone treatment in patients with primary systemic amyloidosis.
III. Time to progression.
OUTLINE: Patients receive bortezomib IV on days 1, 8, and 15 and oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 6 months for 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Light Chain Amyloidosis|
|Study Start Date :||March 2010|
|Primary Completion Date :||March 2011|
|Study Completion Date :||June 2012|
Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.
1.3 mg/m^2, by IV on days 1, 8 and 15 every 28 days
Other Names:Drug: cyclophosphamide
300 mg/m^2, orally, on days 1, 8, 15 & 22 every 28 days.
Other Names:Drug: dexamethasone
40 mg, orally, on days 1, 8, 15 & 22 every 28 days
- Number of Participants With a Confirmed Hematologic Response [ Time Frame: Duration of treatment (up to 12 cycles/months) ]
Response that was confirmed on 2 consecutive evaluations during treatment.
Complete Response(CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and <5% plasma cells in bone marrow.
Very Good Partial Response(VGPR): >=90% reduction in serum M-component; Urine M-Component <=100 mg per 24 hours.
Partial Response(PR): >=50% reduction in serum M-component and/or Urine M-Component >=90% reduction or <200 mg per 24 hours; or >=50% decrease in difference between involved and uninvolved FLC levels.
- Number of Participants With Treatment Related Adverse Events. [ Time Frame: Duration on treatment (up to 12 cycles/months) ]
Adverse events (AE) that are classified as either possibly, probably, or definitely related to study treatment according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE version 3.0). The maximum grade for each type of AE will be recorded for each patient. Grade refers to the severity of the AE.
Grade 1: Mild AE, Grade 2: Moderate AE, Grade 3: Severe AE, Grade 4: Life-threatening or disabling AE, Grade 5: Death related AE
Adverse events will be assessed using NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0.
- Number of Participants With an Organ Response. [ Time Frame: Duration on treatment (up to 12 cycles/months) ]The number of patients that acheived a response in an affected organ.
- Overall Survival [ Time Frame: Duration of Study (up to 5 years) ]Survival time is defined as the time from registration to death due to any cause.
- Time to Disease Progression [ Time Frame: Duration of Study (up to 5 years) ]Time to disease progression is defined as the time from registration to the earliest date of documented disease progression. If a patient dies without a documentation of disease progression the patient will be considered to have had tumor progression at the time of their death
- Duration of Response [ Time Frame: Duration of Study (up to 5 years) ]Duration of response will be calculated from the date of first evidence of response until the date of progression in the subset of patients with confirmed hematologic responses.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01072773
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Study Chair:||Shaji Kumar, M.D.||Mayo Clinic|